Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NVCR Stock Forecast 2025-2026
$10.92
Current Price
$1.22B
Market Cap
Buy 5
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to NVCR Price Targets
+284.6%
To High Target of $42.00
+115.2%
To Median Target of $23.50
+32.8%
To Low Target of $14.50
NVCR Price Momentum
-14.8%
1 Week Change
-23.8%
1 Month Change
-37.4%
1 Year Change
-63.4%
Year-to-Date Change
-68.0%
From 52W High of $34.13
+2.1%
From 52W Low of $10.70
📊 TOP ANALYST CALLS
Did NVCR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Novocure is one of their latest high-conviction picks.
Latest NVCR Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, NVCR has a bullish consensus with a median price target of $23.50 (ranging from $14.50 to $42.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $10.92, the median forecast implies a 115.2% upside. This outlook is supported by 5 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Emily Bodnar at HC Wainwright & Co., projecting a 284.6% upside. Conversely, the most conservative target is provided by Larry Biegelsen at Wells Fargo, suggesting a 32.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NVCR Analyst Ratings
5
Buy
3
Hold
0
Sell
NVCR Price Target Range
Low
$14.50
Average
$23.50
High
$42.00
Current: $10.92
Latest NVCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NVCR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 30, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $42.00 |
| Oct 27, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $23.00 |
| Jul 25, 2025 | Wells Fargo | Larry Biegelsen | Equal-Weight | Downgrade | $14.50 |
| Jul 8, 2025 | Ladenburg Thalmann | Kevin DeGeeter | Buy | Initiates | $30.00 |
| Jun 27, 2025 | Piper Sandler | Jason Bednar | Overweight | Reiterates | $34.00 |
| Apr 23, 2025 | Piper Sandler | Jason Bednar | Overweight | Maintains | $34.00 |
| Apr 16, 2025 | Wedbush | David Nierengarten | Neutral | Maintains | $27.00 |
| Apr 10, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $28.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $38.00 |
| Dec 13, 2024 | Piper Sandler | Jason Bednar | Overweight | Maintains | $42.00 |
| Dec 3, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $38.00 |
| Dec 2, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $38.00 |
| Dec 2, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Upgrade | $30.00 |
| Nov 21, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $30.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $30.00 |
| Oct 16, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Upgrade | $30.00 |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $18.00 |
| Jul 26, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $40.00 |
| Jul 26, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Maintains | $24.00 |
| Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $20.00 |
Novocure Ltd. (NVCR) Competitors
The following stocks are similar to Novocure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Novocure Ltd. (NVCR) Financial Data
Novocure Ltd. has a market capitalization of $1.22B with a P/E ratio of -7.0x. The company generates $642.27M in trailing twelve-month revenue with a -27.7% profit margin.
Revenue growth is +7.8% quarter-over-quarter, while maintaining an operating margin of -21.5% and return on equity of -50.6%.
Valuation Metrics
Market Cap
$1.22B
Enterprise Value
$987.28M
P/E Ratio
-7.0x
PEG Ratio
-0.4x
Price/Sales
1.9x
Growth & Margins
Revenue Growth (YoY)
+7.8%
Gross Margin
+73.9%
Operating Margin
-21.5%
Net Margin
-27.7%
EPS Growth
+5.6%
Financial Health
Cash/Price Ratio
+84.5%
Current Ratio
1.5x
Debt/Equity
233.8x
ROE
-50.6%
ROA
-8.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Novocure Ltd. (NVCR) Business Model
About Novocure Ltd.
What They Do
Develops innovative cancer treatment therapies.
Business Model
Novocure generates revenue primarily through the commercialization of its Tumor Treating Fields (TTFields) therapy, targeting aggressive cancers such as glioblastoma and mesothelioma. The company works closely with healthcare professionals and patients, offering a non-invasive alternative to traditional cancer treatments.
Additional Information
Headquartered in Saint Helier, Jersey, Novocure is dedicated to advancing cancer treatment through extensive clinical research and development, positioning itself as a leader in the specialty cancer treatment market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,488
CEO
Ms. Ashley Cordova
Country
Switzerland
IPO Year
2015
Website
www.novocure.comNovocure Ltd. (NVCR) Latest News & Analysis
Latest News
Quick Summary
NovoCure Limited (NVCR) will hold its Q3 2025 Earnings Call on October 30, 2025, at 8:00 AM EDT, featuring key executives including the CEO and CFO.
Why It Matters
The earnings call provides insights into NovoCure's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Novocure (NASDAQ: NVCR) reported solid Q3 2025 results, with steady sales in glioblastoma, geographic expansion, and progress in clinical and product development for its Tumor Treating Fields therapy.
Why It Matters
Novocure's strong Q3 results highlight effective commercialization and progress in cancer treatment, signaling potential growth and increased investor confidence in the company's future.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NovoCure (NVCR) reported its quarterly performance for Q3 2025, with key metrics being compared to Wall Street estimates and results from the same period last year.
Why It Matters
NovoCure's quarterly performance and comparisons to estimates and previous results provide critical insights into growth trends, profitability, and market expectations, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
NovoCure (NVCR) reported a quarterly loss of $0.33 per share, better than the estimated loss of $0.42, but worse than a loss of $0.28 per share from the previous year.
Why It Matters
NovoCure's smaller-than-expected loss signals potential operational improvements, potentially boosting investor confidence and affecting stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Novocure (NASDAQ: NVCR) will present data on Tumor Treating Fields at the EANO Meeting in Prague (Oct 16-19) and ESMO Congress in Berlin (Oct 17-21) in 2025.
Why It Matters
Novocure's upcoming presentations at major oncology congresses could drive investor interest, indicating potential advancements in cancer treatment and impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Novocure Limited (NVCR) is rated BUY, supported by regulatory approvals, strong clinical results, and a late-stage cancer therapy pipeline. Key upcoming catalysts include Q3 results and METIS, PANOVA-3 updates.
Why It Matters
Novocure's expanding approvals and breakthrough results position it favorably in oncology. Upcoming catalysts and solid financials enhance its growth potential, making NVCR a strong investment choice.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About NVCR Stock
What is Novocure Ltd.'s (NVCR) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Novocure Ltd. (NVCR) has a median price target of $23.50. The highest price target is $42.00 and the lowest is $14.50.
Is NVCR stock a good investment in 2026?
According to current analyst ratings, NVCR has 5 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NVCR stock?
Wall Street analysts predict NVCR stock could reach $23.50 in the next 12 months. This represents a 115.2% increase from the current price of $10.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Novocure Ltd.'s business model?
Novocure generates revenue primarily through the commercialization of its Tumor Treating Fields (TTFields) therapy, targeting aggressive cancers such as glioblastoma and mesothelioma. The company works closely with healthcare professionals and patients, offering a non-invasive alternative to traditional cancer treatments.
What is the highest forecasted price for NVCR Novocure Ltd.?
The highest price target for NVCR is $42.00 from Emily Bodnar at HC Wainwright & Co., which represents a 284.6% increase from the current price of $10.92.
What is the lowest forecasted price for NVCR Novocure Ltd.?
The lowest price target for NVCR is $14.50 from Larry Biegelsen at Wells Fargo, which represents a 32.8% increase from the current price of $10.92.
What is the overall NVCR consensus from analysts for Novocure Ltd.?
The overall analyst consensus for NVCR is bullish. Out of 15 Wall Street analysts, 5 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $23.50.
How accurate are NVCR stock price projections?
Stock price projections, including those for Novocure Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 6:10 AM UTC